Thank you for promoting this - so much to be done if we are to improve outcomes for men globally The Lancet The ICR The Royal Marsden NHS Foundation Trust

Great to have the opportunity to discuss with my friend Thomas Zilli the current status and future of prostate/mets radiotherapy in #prostatecancer at #APCCC24 .

Thanks Uromigos Tom Powles Brian Rini, MD for the invitation!

Thanks Yüksel, was wonderful to have you with us!

Cannot wait! Two great minds in a Swiss train can only end in excellent results!

Thanks Nick! A big part of the success are the panelists (including you of course!), who are fantastic and helped so much. And the amazing participants who were so interactive and attentive!
A heartfelt thanks to all of you!

Great session and great panel to discuss the ⁦The Lancet⁩ Prostate Cancer Commission. Many thanks to #APCCC24 for featuring prominently. Will be a fantastic launch pad for new initiatives. ⁦The ICR⁩ thelancet.com/pdfs/journals/…

Many thanks and congratulations to silke gillessen and aurelius omlin and the superb #APCCC24 team on another spectacularly successful meeting! A clear consensus (unanimously) a great success 😀

Great pleasure to have so many of the #Stampede2 team here in Lugano for #APCCC24 ⁦silke gillessen⁩ ⁦aurelius omlin⁩ always such a great meeting 😀⁦MRC Clinical Trials Unit at UCL⁩

Congrats @SilkeGillessen & aurelius omlin on a truly outstanding Advanced Prostate Cancer Consensus Conference #APCCC24

When Oligometastatix (aka me) and Pelvix (aka Vedang Murthy) share a 3h train ride home from #APCCC24 , new trials are born! Be ready for us #APCCC30 ! Thanks again silke gillessen and aurelius omlin for having us.

Sad to be leaving #APCCC24 and beautiful Lugano, but what a fantastic meeting it has been. Plenty to think about, and some practice-changing information. Thank you silke gillessen aurelius omlin Advanced Prostate Cancer Consensus Conference for giving me the joy and privilege of being part of such a great community.

Michael Hofman Alternative PSMA ligands for diagnostics & treatment:
Are they interchangeable? Outstanding overview!
☢️ Do they have similar safety & efficacy: radioequivalent
☢️ Precision medicine: patient selections is key
☢️ Please: don't treat blindly!
☢️ Best PSMA radiotracer…

Extraordinary mHSPCa session
Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin tombal Thomas Zilli Nick James
Dana Rathkopf
Christopher Sweeney, MBBS Maria De Santis any many others 🏆

Fantastic to see data from STAMPEDE and STRATOSPhere presented as part of the discussion on future changes for men with metastatic hormone sensitive prostate cancer from AttardLab this morning

#APCCC24 #prostatecancer #research

Nick James Thanks Nick. This will only happen when we all as investigators (and with patient advocacy) refuse to do such trials when offered to us. We all need to do better because it’s 2024 and we know this should no longer be acceptable in trial design / registration strategy. #APCCC24

Episode 1 of our new podcast looking behind the scenes at trial set up now live - ethics and regulatory issues. Episode 2 on routine data access soon. Future episodes: first SIV #STAMPEDE2 , international set up Hoda Abdel-Aty Trials & Tribulations | Oncology Trials Podcast open.spotify.com/episode/1nn556…

Thought provoking lecture by Ian Davis on the challenges of interpreting data on treatment sequencing in metastatic #prostatecancer and what is the way forward #APCCC24

No consensus about intermittent systemic therapy at #APCCC24 in mHSPC #prostatecancer , even in deep PSA remission or when MDT is used.

Important avenue for prospective trials, such as tombal PEACE6 de-Escalate

Prof Noel Clarke highlights our data from STAMPEDE on long term fracture related hospitalisation amongst patients with advanced prostate cancer at #APCCC24 Advanced Prostate Cancer Consensus Conference

Craig Jones Peter Dutey Matt Sydes Nick James GU Cancer Research group Division of Cancer Sciences MRC Clinical Trials Unit at UCL

Absolutely. Not advocating not using it, just emphasising that we need to discuss side effects with our patients.